Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.
J Cardiovasc Pharmacol
; 76(1): 42-49, 2020 07.
Article
en En
| MEDLINE
| ID: mdl-32265370
ABSTRACT
Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pericarditis
/
Proteína Antagonista del Receptor de Interleucina 1
/
Antiinflamatorios
Tipo de estudio:
Diagnostic_studies
/
Guideline
Límite:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Cardiovasc Pharmacol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Brasil